- 专利标题： Afucosylated Anti-FGFR2IIIB Antibodies
-
申请号： US17554423申请日： 2021-12-17
-
公开(公告)号： US20220168416A1公开(公告)日： 2022-06-02
- 发明人: Thomas Harding , Kristen Pierce , Namrata Patil , Thomas Brennan , Julie Hambleton
- 申请人： Five Prime Therapeutics, Inc.
- 申请人地址： US CA Thousand Oaks
- 专利权人： Five Prime Therapeutics, Inc.
- 当前专利权人： Five Prime Therapeutics, Inc.
- 当前专利权人地址： US CA Thousand Oaks
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; C07K16/28 ; A61K33/243 ; A61K31/337 ; A61K31/513 ; A61K45/06
摘要：
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
信息查询
